Celldex (CLDX), at EADV 2025, disclosed new data from its Phase 2 study assessing barzolvolimab in CSU, showing that barzo has rapid efficacy in Chronic Spontaneous Urticaria patients with both low and normal/high baseline IgE levels, H.C. Wainwright tells investors in a research note. The firm, which has a Buy rating and $42 price target on the shares, says data further differentiates the product from competitors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex announces new barzolvolimab data at EADV congress
- Celldex Therapeutics Advances in Prurigo Nodularis Treatment with Barzolvolimab Study
- Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
- Celldex Therapeutics Advances Phase 3 Trial for Chronic Spontaneous Urticaria Treatment
- 3 Best Stocks to Buy Now, 8/25/2025, According to Top Analysts